AQST Aquestive Therapeutics, Inc.
Company Analysis
Latest News
Aquestive Therapeutics Resubmits NDA to FDA for Anaphylm Sublingual Film
Aquestive Therapeutics has resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its lead product candidate, Anaphylm...
🟢 Aquestive Therapeutics rises 5.0% — Biotech Sector Rallies on Major AI Collaboration Deal and Positive Clinical News
With Biotech (XBI) up 2.1%, this looks like a sector-led move rather than a company-specific surprise. The biotechnology sector is trading higher, driven by a...
Aquestive Resubmits New Drug Application to FDA for Anaphylm™ Sublingual Film
Aquestive Therapeutics announced it has resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Anaphylm™...
Aquestive Resubmits Anaphylm NDA, Slashing Emergency Opening Time to 3 Seconds
Aquestive Therapeutics resubmitted its New Drug Application (NDA) to the FDA for Anaphylm. This under-the-tongue film treats severe allergic reactions,...
🟢 Aquestive Therapeutics is trading 5% up in pre-market as Nasdaq Composite gains 0.52%
Aquestive Therapeutics is trading at $5.07, up 5.48%, with the move appearing aligned with a firm pre-market backdrop. - No new company-specific announcement...
🟢 Aquestive Therapeutics is trading 5% up today amid biotech-sector momentum
Aquestive Therapeutics is trading 5% up now at $5.33, with biotech-sector momentum appearing to drive the move. - Biotech ETF XBI rose 2.06% during regular...
🟢 Aquestive Therapeutics rises 5.1% — Biotech Sector Gains Amid Broad Market Rally and Positive Sentiment
With Biotech (XBI) up 2.1%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, represented by the XBI ETF, is...
🟢 Aquestive Therapeutics is trading 8.9% up today as biotech shares rally on Moderna trial results
Aquestive Therapeutics is trading 8.9% up at $4.71, outperforming its recent closes as biotechnology shares rally on positive Moderna cancer-vaccine trial...
🟢 Aquestive Therapeutics is trading 5.88% up in pre-market with no clear catalyst identified
Aquestive Therapeutics is trading 5.88% up in pre-market at $4.50, versus the August 14, 2026 close of $4.25; no new company-specific announcement explaining...
🔴 Aquestive Therapeutics is trading 5% down today after wider-than-expected Q2 loss
Aquestive Therapeutics is trading 5% down now at $4.04 after investors continued weighing its August 11 earnings. - Second-quarter revenue increased 38% year...
Aquestive Therapeutics second quarter 2026 revenue of $13.8M missed estimates as Anaphylm resubmission remains on track
Aquestive Therapeutics reported second quarter 2026 revenue of $13.8 million, representing a 38% increase year-over-year but falling short of the $14.2 million...
🟢 Aquestive Therapeutics is trading 7.22% up today after positive Anaphylm results support FDA resubmission
Aquestive Therapeutics is trading 7.22% up now at $4.60 after positive Anaphylm human-factors and pharmacokinetic results supported its planned third-quarter...
🟢 Aquestive Therapeutics is trading 5.59% up in pre-market after positive Anaphylm results support planned FDA resubmission
Aquestive Therapeutics is trading 5.59% up now at $4.53 after positive Anaphylm human-factors and pharmacokinetic results supported a planned third-quarter...
🟢 Aquestive Therapeutics is trading 13.96% up today after Anaphylm studies cleared a key FDA hurdle
Aquestive Therapeutics is trading 13.96% up now at $4.49 after Anaphylm’s usability and drug-absorption studies cleared a key FDA hurdle, strengthening the...
🟢 Aquestive Therapeutics is trading 12% up in pre-market today after Anaphylm studies clear key FDA hurdle
Aquestive Therapeutics is trading 12.18% up now at $4.42 after its needle-free Anaphylm epinephrine film passed usability and drug-absorption studies, clearing...
Aquestive Clears a Key FDA Hurdle for Its Needle-Free Allergy Drug — But Can a $630 Million Company Really Take On EpiPen?
Shares of Aquestive Therapeutics jumped +9.1% to $4.30 Monday morning after the company reported that its under-the-tongue epinephrine film — a...
🟢 Aquestive Therapeutics is trading 9.14% up in pre-market after positive Anaphylm usability and pharmacokinetic results
Aquestive Therapeutics is trading at $4.30 (+9.14%) after announcing positive topline human-factors and pharmacokinetic study results for Anaphylm. - The data...
Aquestive Announces Positive Study Results for Anaphylm™, Plans Q3 NDA Resubmission
Aquestive Therapeutics announced positive topline results from its human factors (HF) and pharmacokinetic (PK) studies for Anaphylm™ (dibutepinephrine)...
Aquestive Therapeutics Inc Q2 2026 Earnings Preview: What Analysts Expect on August 11, 2026
Wall Street analysts expect Aquestive Therapeutics to report Q2 2026 revenue of $14.22 million and a net loss of $0.11 per share, with the current $4.25 share...
🔴 Aquestive Therapeutics Inc is trading 5.66% down
AQST is trading at $4.00, down 5.66%.